meningeal carcinomatosis/dijareja

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

10 rezultati

A Case of Leptomeningeal Carcinomatosis from Aggressive Metastatic Prostate Cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Leptomeningeal carcinomatosis (LC) is a rare leptomeningeal spread of diffusely metastatic tumors. It occurs more commonly with hematologic tumors, less commonly with solid tumors, and is exceedingly rare in prostate cancer. Due to its scarcity, it has traditionally been difficult to diagnose LC but

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Pneumatosis intestinalis (PI) is a rare complication of chemotherapy, characterized by multiple gas accumulations within the bowel wall. METHODS A 71-year-old woman with epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma was admitted to our hospital because of

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Background: Up to 40% of patients with non-small cell lung cancer (NSCLC) and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nerve system (CNS), either as brain

A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Both interferon-alpha (IFN-alpha) and alpha-difluoromethylornithine (DFMO) have shown modest activity as single-agent therapy in the treatment of malignant melanoma. Several investigators have demonstrated true synergism in vitro of the combination of DFMO and IFN-alpha against human tumor cells,

Phase II study of docetaxel in advanced soft tissue sarcomas.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Because of its unusual mechanism of action, docetaxel was selected for study in advanced soft tissue sarcomas of adults as part of a search for new active antisarcoma agents. Patients at least 18 years old with measurable histologically proven advanced nonosseous sarcomas were enrolled if they had

[A case of head metastases of breast cancer successfully treated with radiation therapy and docetaxel].

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

A 68-year-old female underwent radical mastectomy for left breast cancer in April, 1995. She was treated with conventional combination chemotherapy (CEF) before and after surgery as an adjuvant therapy. She was treated with oral tamoxifen (TAM) and/or medroxyprogesterone (MPA) and doxifluridine

Subacute transient encephalopathy induced by erlotinib.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Erlotinib (Tarceva) is a selective small-molecule inhibitor of HER1/EGFR tyrosine kinases that is especially effective for treating non-small cell lung cancer (NSCLC) harboring a constitutively active EGFR mutation. Erlotinib treatment frequently induces adverse effects such as skin rashes and

Phase II trial of patupilone in patients with brain metastases from breast cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND For patients with progressive breast cancer brain metastasis (BCBM) after whole brain radiotherapy (WBRT), few options exist. Patupilone is an epothilone that crosses the blood-brain barrier. We hypothesized that patupilone would produce a 35% 3-month CNS progression-free survival in

[Clinical Observation of Erlotnib in the Treatment of Non-small Cell Lung Cancer with Multimetastases in Elderly Patients.].

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Erlotnib is the inhibitor of epidemic growth factor receptor and mainly used to treat non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the antitumor efficacy and toxicity of erlotnib in the treatment of Chinese elderly NSCLC patients with

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

BACKGROUND Erlotinib shows large inter-patient pharmacokinetic variability, but the impact of early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully investigated. The primary objective of this study was to clarify the population

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta naukom

Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima